Bayer completes Phase 1 drug interaction study of sevabertinib with metformin
Bayer finished a Phase 1 trial examining how sevabertinib affects metformin levels in healthy adults, according to a clinicaltrials.gov record updated October 26, 2026.
- Sevabertinib (BAY 2927088), Phase 1, healthy participants: the trial examined whether sevabertinib might inhibit kidney transporter proteins called MATE1 and MATE2-K that normally help clear metformin from the body.1 The study is listed as completed, with 42 participants enrolled1 and an actual primary completion date of October 6, 2026.1
Fact check notes
- Checker's noteThe phrase 'Bayer's listed sponsored trial activity for the week' is an unsupported framing claim not found in the source, which only documents a single trial record without reference to weekly activity.
- Sentence removed
Bayer's listed sponsored trial activity for the week centers on a single completed early-phase pharmacokinetic study.
unsupported: Source contains no information about a 'week' of sponsored trial activity; this is an unverifiable framing claim not supported by the single-study record.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.